Evidence map›Paper›PMID 40284929›Full record

ArticleViruses2025

Subtype AD Recombinant HIV-1 Transmitted/Founder Viruses Are Less Sensitive to Type I Interferons than Subtype D.

Denis Omara, Fortunate Natwijuka, Anne Kapaata, Frank Kato, Laban Kato, Christian Ndekezi, Angella Nakyanzi, Mercy L Ayebale, Ling Yue, Eric Hunter and 4 more

Abstract read
In one paragraph

Article in Viruses, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Denis OmaraDepartment of Immunology and Molecular Biology, School of Biomedical Sciences, College of Health Sciences, Makerere University, Kampala P.O. Box 7062, Uganda.ORCID 0000-0001-7936-1754
Fortunate NatwijukaDepartment of Immunology and Molecular Biology, School of Biomedical Sciences, College of Health Sciences, Makerere University, Kampala P.O. Box 7062, Uganda.
Anne KapaataMedical Research Council, Uganda Virus Research Institute & London School of Hygiene and Tropical Medicine (MRC/UVRI & LSHTM), Uganda Research Unit, Entebbe P.O. Box 49, Uganda.ORCID 0000-0002-0726-1276
Frank KatoDepartment of Immunology and Molecular Biology, School of Biomedical Sciences, College of Health Sciences, Makerere University, Kampala P.O. Box 7062, Uganda.ORCID 0000-0001-5075-0756
Laban KatoMedical Research Council, Uganda Virus Research Institute & London School of Hygiene and Tropical Medicine (MRC/UVRI & LSHTM), Uganda Research Unit, Entebbe P.O. Box 49, Uganda.
Christian NdekeziDepartment of Immunology and Molecular Biology, School of Biomedical Sciences, College of Health Sciences, Makerere University, Kampala P.O. Box 7062, Uganda.ORCID 0000-0001-5068-1746
Angella NakyanziUganda Virus Research Institute (UVRI), Entebbe P.O. Box 49, Uganda.
Mercy L AyebaleMedical Research Council, Uganda Virus Research Institute & London School of Hygiene and Tropical Medicine (MRC/UVRI & LSHTM), Uganda Research Unit, Entebbe P.O. Box 49, Uganda.
Ling YueEmory Vaccine Center, Emory National Primate Research Center, Atlanta, GA 30329, USA.
Eric HunterEmory Vaccine Center, Emory National Primate Research Center, Atlanta, GA 30329, USA.ORCID 0000-0002-4273-8631
Obondo J SandeDepartment of Immunology and Molecular Biology, School of Biomedical Sciences, College of Health Sciences, Makerere University, Kampala P.O. Box 7062, Uganda.ORCID 0000-0002-2301-5980
Christina OchsenbauerDepartment of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294, USA.ORCID 0000-0003-1166-5879
Pontiano KaleebuMedical Research Council, Uganda Virus Research Institute & London School of Hygiene and Tropical Medicine (MRC/UVRI & LSHTM), Uganda Research Unit, Entebbe P.O. Box 49, Uganda.
Sheila N BalindaMedical Research Council, Uganda Virus Research Institute & London School of Hygiene and Tropical Medicine (MRC/UVRI & LSHTM), Uganda Research Unit, Entebbe P.O. Box 49, Uganda.

Funding

Deciphering the impact of sex in early subtype C HIV infection and during HARTR01AI172740 · NIAID · EMORY UNIVERSITY · PI Eric Hunter · 2022 to 2026
$4.3M
NIAID NIH HHS R01 AI172740Sub-Saharan African Network for TB/HIV research Excellence (SANTHE) research fellowship grant and The Africa Center of Excellence in Materials, Product Development and Nanotechnology (MAPRONANO ACE) research scholarship grant. MAP/MAS/054 2019
6 · The paper itself

Abstract

Initial interactions between HIV-1 and the immune system at mucosal exposure sites play a critical role in determining whether the virus is eliminated or progresses to establish systemic infection. The virus that successfully crosses the mucosal barrier to establish infection in the new host is referred to as the transmitted/founder (TF) virus. Following mucosal HIV-1 transmission, type 1 interferons (IFN-I) are rapidly induced at sites of initial virus replication. The resistance of TF variants to these antiviral effects of the IFN-I has been studied among HIV-1 subtypes B and C. However, their role in restricting HIV-1 replication among subtypes D and AD recombinant remains unexplored. This study assessed the sensitivity of HIV-1 subtype D and AD recombinant TF viruses to IFN-I by infecting peripheral blood mononuclear cells in vitro with infectious molecular clones of these viruses. Cells were exposed to varying concentrations of interferon-α and interferon-β, and viral replicative capacity was measured using HIV-1 p24 antigen ELISA from culture supernatants. Sensitivity to IFN-I was quantified based on viral replication levels. The results showed that interferon-α was more effective in inhibiting viral replication than interferon-β, regardless of the varying amounts of IFN-I used. However, recombinant AD viruses were found to be more resistant to the antiviral effects of IFN-I compared to subtype D viruses. These findings highlight the differential sensitivity of HIV-1 subtypes AD recombinant and D TF viruses to IFN-I and underscore the potential of IFN-I as a therapeutic strategy to target TF viruses and reduce HIV-1 transmission, particularly in populations where subtype D is prevalent.

Indexed as

HIV-1HIV InfectionsInterferon Type IHumansInterferon-alphaLeukocytes, MononuclearVirus ReplicationInterferon-alphaInterferon Type IHIV-1resistancesensitivitytransmitter founder virusestype one interferons

Identifiers

PMID40284929
PMCPMC12031311

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.